A Simplified Test to Assess Flavor in COVID-19 Patients

Sponsor
Federico II University (Other)
Overall Status
Completed
CT.gov ID
NCT04840966
Collaborator
(none)
111
1
8.4
13.2

Study Details

Study Description

Brief Summary

The Flavor test has been developed and validated by our group to assess retro-nasal olfactory performances.

The original flavor test has been simplified, with the great advantage to be self-administrable for COVID-19 patients in isolation, without any risk to health professionals.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Flavor test
  • Other: Self-assesment questionnaire

Detailed Description

Smell and taste dysfunctions (STDs) are symptoms associated with COVID-19 syndrome, even if their incidence is still uncertain and variable. In this study, the effects of SARS-CoV-2 infection on chemosensory function have been investigated using both a self-reporting questionnaire on smell and flavor perception, and a simplified flavor test. A total of 111 subjects (19 hospitalized [HOS] and 37 home-isolated [HI] COVID-19 patients, and 55 healthy controls [CTRL]) were enrolled in the study. The flavor test used consists in the self-administration of four solution with a pure olfactory stimulus (coffee), a mixed olfactory-trigeminal stimulus (peppermint), and a complex chemical mixture (banana).

After SARS-CoV-2 infection, HOS and HI patients reported similar frequency of STDs, with a significant reduction of both smell and flavor self-estimated perception.

The aromas of the Flavor test were recognized by HI and HOS COVID-19 patients similarly to CTRL, however the intensity of the perceived aromas was significantly lower in patients compared to controls.

This suggests that a chemosensory impairment is present after SARS-CoV-2 infection, and the modified "flavor test" could be a novel self-administering objective screening test to assess STDs in COVID-19 patients.

Study Design

Study Type:
Observational
Actual Enrollment :
111 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Simplified Flavor Test for Self-administation in COVID-19 Positive Patients
Actual Study Start Date :
May 5, 2020
Actual Primary Completion Date :
Jan 15, 2021
Actual Study Completion Date :
Jan 15, 2021

Arms and Interventions

Arm Intervention/Treatment
HOS: hospitalized COVID19 patients

Patients positive to COVID19 hospitalized

Diagnostic Test: Flavor test
A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Other: Self-assesment questionnaire
Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to "no smell/flavor perception" and 10 corresponding to "excellent smell/flavor perception".

HI: Home-isolated COVID19 patients

Home-isolated patients positive to COVID19

Diagnostic Test: Flavor test
A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Other: Self-assesment questionnaire
Questionnaire to score subjective chemosensory function (smell and flavor) before and after COVID-19 using a 0-10 scale with 0 corresponding to "no smell/flavor perception" and 10 corresponding to "excellent smell/flavor perception".

CTRL: Healthy controls

Healthy COVID19 negative subjects

Diagnostic Test: Flavor test
A simplified self-administrable flavor test has been proposted to all the enrolled subjects

Outcome Measures

Primary Outcome Measures

  1. Flavor perception [Apr, 2020- Jan, 2021]

    To assess qualitative flavor perception

Secondary Outcome Measures

  1. Flavor perception intensity [Apr, 2020- Jan, 2021]

    To assess quantitative flavor perception

Other Outcome Measures

  1. Comparison with self-estimated flavor perception [Apr, 2020- Jan, 2021]

    To compare results of the test with self-assessed flavor and smell perception

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Adults (≥18 years of age) that gave their written informed consent to the study

  • Diagnosis of COVID-19 was confirmed by PCR of nasopharyngeal swab (HI or HOS)

  • Negative COVID-19 nasopharyngeal swab (CTRL)

  • Subjects with no critical conditions and able to understand the protocol

Exclusion Criteria:
  • nasal obstruction or previous nasal diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dipartimento di Medicina Clinica e Chirurgia Napoli Italy 80131

Sponsors and Collaborators

  • Federico II University

Investigators

  • Principal Investigator: Paolo E Macchia, M.D., Ph.D., Federico II University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Paolo Emidio Macchia, Md., Ph.D., Federico II University
ClinicalTrials.gov Identifier:
NCT04840966
Other Study ID Numbers:
  • PM0001/2020
First Posted:
Apr 12, 2021
Last Update Posted:
Apr 15, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Paolo Emidio Macchia, Md., Ph.D., Federico II University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 15, 2021